Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H7O6P.2K.3H2O |
Molecular Weight | 302.3003 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[K+].[K+].OCC(CO)OP([O-])([O-])=O
InChI
InChIKey=OYGPDLGTPYXTHU-UHFFFAOYSA-L
InChI=1S/C3H9O6P.2K.3H2O/c4-1-3(2-5)9-10(6,7)8;;;;;/h3-5H,1-2H2,(H2,6,7,8);;;3*1H2/q;2*+1;;;/p-2
DescriptionSources: http://www.thegoodscentscompany.com/data/rw1610691.html | http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=multi_vitmin_suppl | https://www.google.ch/patents/US20090169685 | https://www.accessdata.fda.gov/scripts/fcn/fcndetailnavigation.cfm?rpt=eafuslisting&id=1747 | http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500015774.pdfhttps://www.exercise.com/supplements/potassium-glycerophosphate
Sources: http://www.thegoodscentscompany.com/data/rw1610691.html | http://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq.do?atid=multi_vitmin_suppl | https://www.google.ch/patents/US20090169685 | https://www.accessdata.fda.gov/scripts/fcn/fcndetailnavigation.cfm?rpt=eafuslisting&id=1747 | http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500015774.pdfhttps://www.exercise.com/supplements/potassium-glycerophosphate
Potassium Glycerophosphate is a source of potassium. It is used in the treatment of nutritional deficiencies. Potassium supplements can be an important part of the recovery from or prevention of many different ailments and diseases. The most common of these include helping lower blood pressure and serving as a stroke preventative. Potassium can also be used to lower levels of calcium, to help with certain diseases including Alzheimer’s and Meniere’s. It may also help with some more common issues such as a common allergy, migraines, heavy acne, alcohol abuse, dizziness and confusion, extreme fatigue, recurring constipation, insomnia, anger and aggression, irregular heartbeat and stress. Potassium can either be taken as a supplement by mouth or it can be given intravenously to certain patients who require a faster dosing of the mineral or cannot take it orally.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Minadex Approved UseAs a treatment for vitamin and mineral deficiency and as an appetite stimulant during and after illness Launch Date1995 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
13UV61K0I2
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY | |||
|
76963789
Created by
admin on Fri Dec 15 15:54:56 GMT 2023 , Edited by admin on Fri Dec 15 15:54:56 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD